Abbott Laboratories Healthcare - Medical Equipment SWOT Report

Summary

Abbott Laboratories - Healthcare - Medical Equipment SWOT Report is a comprehensive report of the company including both quantitative and qualitative research. The report examines the company's business structure and operations, history and products. The report provides strategic insight on the company in the form of a SWOT analysis. This studies the major internal factors which will affect the company's performance e.g. size, strength, cost, revenues and strategy as well as external factors e.g. competitive positioning and industry trends. There is a forward-looking discussion of the opportunities the company can exploit and the threats facing it.

Scope

• Critical appraisal of the company's positioning using SWOT analysis.
• Company information, including business descriptions, company history, product lines, key competitors and key employee biographies.

Reasons to buy

• Support business/sales activities by understanding customers businesses better.
• Identify prospective partners and suppliers.
• Capitalize on your competitors weaknesses and target the market opportunities available to them.

Contents

• 1 List of Tables
• 2 Company Snapshot
  • 2.1 Key Information
  • 2.2 Company Overview
  • 2.3 Financial Performance
  • 2.4 Industry Outlook - Cardiovascular Devices
  • 2.5 Industry Outlook - In Vitro Diagnostics
• 3 Business Description
  • 3.1 Business Overview
  • 3.2 Diagnostics
    • 3.2.1 Overview
    • 3.2.2 Financials
    • 3.2.3 Market View
    • 3.2.4 Key Strategies
  • 3.3 Nutritionals
    • 3.3.1 Overview
    • 3.3.2 Financials
    • 3.3.3 Market View
    • 3.3.4 Key Strategies
  • 3.4 Pharmaceuticals
    • 3.4.1 Overview
    • 3.4.2 Financials
    • 3.4.3 Market View
    • 3.4.4 Key Strategies
  • 3.5 Vascular
    • 3.5.1 Overview
    • 3.5.2 Financials
    • 3.5.3 Market View
    • 3.5.4 Key Strategies
  • 3.6 Major Products and Services
    • 3.6.1 Overview
• 4 History
• 5 SWOT Analysis
  • 5.1 Overview
  • 5.2 Abbott Laboratories Strengths
    • 5.2.1 Abbott Vascular
    • 5.2.2 Strong R&D capability
    • 5.2.3 Financial strength
  • 5.3 Abbott Laboratories Weaknesses
    • 5.3.1 Patent litigation
    • 5.3.2 Relatively low operating margin
  • 5.4 Abbott Laboratories Opportunities
    • 5.4.1 Increasing therapeutic coverage of Humira
    • 5.4.2 Acquisition of Kos Pharmaceuticals
    • 5.4.3 Growing blood glucose testing market
  • 5.5 Abbott Laboratories Threats
    • 5.5.1 Environmental matters
    • 5.5.2 Pending lawsuits
    • 5.5.3 Industry consolidation
• 6 Competitors
• 7 Key Employees
• 8 Key Employee Biographies
• 9 Company Statement
• 10 Locations And Subsidiaries
  • 10.1 Head Office
  • 10.2 Other Locations & Subsidiaries
• 11 Recent Developments
  • 11.1 Strategy And Business Planning
    • 11.1.1 Jul 11, 2007: Abbott Announces Termination Of Contract With GE
  • 11.2 Financial Announcements
    • 11.2.1 Aug 04, 2008: Abbott Spends $1 Million On Lobbying In 2Q 2008
    • 11.2.2 Jul 16, 2008: Abbott Reports 2Q 2008 Results
    • 11.2.3 Jun 30, 2008: Abbott To Declare Q2 2008 Results
    • 11.2.4 Jun 06, 2008: Abbott Declares Quarterly Dividend
    • 11.2.5 Apr 16, 2008: Abbott Declares Quarterly Dividend
    • 11.2.6 Apr 16, 2008: Abbott Declares Q1 2008 Results
    • 11.2.7 Apr 01, 2008: Abbott To Declare Q1 2008 Results
    • 11.2.8 Jan 23, 2008: Abbott Declares Q4 2007 Results
    • 11.2.9 Jan 03, 2008: Abbott To Declare Q4 And Year-End 2007 Results
    • 11.2.10 Dec 14, 2007: Abbott Declares Quarterly Dividend
    • 11.2.11 Oct 17, 2007: Abbott Declares Quarterly Dividend
    • 11.2.12 Oct 17, 2007: Abbott Declares Q3 2007 Results
    • 11.2.13 Jul 18, 2007: Abbott Reports Q2 2007 Results
    • 11.2.14 Jun 14, 2007: Abbott Declares Quarterly Dividend
    • 11.2.15 Apr 18, 2007: Abbott Reports Q1 2007 Results
    • 11.2.16 Apr 18, 2007: Abbott Declares Quarterly Dividend
    • 11.2.17 Jan 24, 2007: Abbott Reports Q4 2006 Results
    • 11.2.18 Jan 24, 2007: Abbott Declares Quarterly Dividend
    • 11.2.19 Oct 18, 2006: Abbott Reports Q3 2006 Results
    • 11.2.20 Oct 18, 2006: Abbott Declares Quarterly Dividend
    • 11.2.21 Oct 18, 2006: Abbott Announces Share Repurchase Program
    • 11.2.22 Jul 19, 2006: Abbott Reports Q2 2006 Results
    • 11.2.23 Jul 19, 2006: Abbott Declares Quarterly Dividend
    • 11.2.24 Apr 19, 2006: Abbott Reports Q1 2006 Results
    • 11.2.25 Apr 19, 2006: Abbott Declares Quarterly Dividend
  • 11.3 Corporate Communications
    • 11.3.1 Aug 03, 2007: Abbott COO To Retire
    • 11.3.2 Dec 20, 2006: Abbott To Voluntarily Delist From NYSE Arca
    • 11.3.3 Jan 20, 2006: Abbott Names New Director To The Board
  • 11.4 Legal and Regulatory
    • 11.4.1 Jul 25, 2008: Abbott Gets US Subpoena On Bile-duct Stents
    • 11.4.2 Apr 14, 2008: Innogenetics Receives $9.5 Million In Settlement And Licensing Fees From Abbott
  • 11.5 Product News
    • 11.5.1 Apr 22, 2008: Smiths Medical To Promote And Distribute Abbott's FreeStyle Navigator Continuous Glucose Monitoring System
    • 11.5.2 Apr 14, 2008: Abbott FreeStyle Freedom Lite Blood Glucose Monitoring System Now Available With No Coding For People With Diabetes
    • 11.5.3 Mar 14, 2008: Abbott Laboratories Releases The Lancet Publishes Results Of A Fully Bioabsorbable Drug Eluting Coronary Stent
    • 11.5.4 Jan 18, 2008: Abbott Announces Approval Of First Fully Automated Blood Screening Test For HTLV-I/HTLV-II
    • 11.5.5 Oct 22, 2007: Abbott Announces Positive One-Year Results From The World's First Clinical Trial Of A Fully Bioabsorbable Drug Eluting Coronary Stent
    • 11.5.6 Jul 08, 2007: The FreeStyle Navigator Continuous Glucose Monitor Is Approved In Europe
    • 11.5.7 Oct 24, 2006: Abbott Reports Initial Results From World's First Clinical Trial Featuring A Fully Bioabsorbable Drug-eluting Coronary Stent
  • 11.6 Product Approvals
    • 11.6.1 Jan 18, 2008: Abbott Announces Approval Of First Fully Automated Blood Screening Test For HTLV-I/HTLV-II
    • 11.6.2 Jul 08, 2007: The FreeStyle Navigator Continuous Glucose Monitor Is Approved In Europe
  • 11.7 Clinical Trials
    • 11.7.1 Mar 14, 2008: Abbott Laboratories Releases The Lancet Publishes Results Of A Fully Bioabsorbable Drug Eluting Coronary Stent
    • 11.7.2 Oct 22, 2007: Abbott Announces Positive One-Year Results From The World's First Clinical Trial Of A Fully Bioabsorbable Drug Eluting Coronary Stent
    • 11.7.3 Oct 24, 2006: Abbott Reports Initial Results From World's First Clinical Trial Featuring A Fully Bioabsorbable Drug-eluting Coronary Stent
  • 11.8 Other Significant Developments
    • 11.8.1 May 16, 2008: Abbott Contributes To Disaster Relief Efforts In China And Myanmar
    • 11.8.2 Jun 04, 2007: Abbott Signs Agreement With Novation For Diagnostic Equipment And Tests
    • 11.8.3 Apr 16, 2007: Abbott And Premier Sign Contract For Diagnostic Tests
• 12 Appendix
  • 12.1 Methodology
  • 12.2 About Global Markets Direct
  • 12.3 Contact Us
  • 12.4 Disclaimer
• 1 List of Tables
  • Table 1: Abbott Laboratories,Key Facts, 2007
  • Table 2: Abbott Laboratories, SWOT Analysis , 2007
  • Table 3: Abbott Laboratories, Key Employees, 2007
  • Table 4: Abbott Laboratories, Other Locations
  • Table 5: Abbott Laboratories, Subsidiaries